Production of Recombinant Nucleocapsid Protein SARSN1 and Its Use for Assessing the Immune Response in Mice after Vaccination with a Live Probiotic Vaccine Containing the Coronavirus Nucleocapsid Protein.

IF 0.6 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Bulletin of Experimental Biology and Medicine Pub Date : 2025-07-01 Epub Date: 2025-09-25 DOI:10.1007/s10517-025-06482-z

T V Gupalova, E A Bormotova, G F Leontieva, T A Kramskaya, Yu A Desheva, A N Suvorov

引用次数: 0

Abstract

The nucleocapsid (N) protein of the severe acute respiratory syndrome coronavirus (SARSCoV) is the most abundant structural protein in virus-infected cells. Its primary function is to pack ~30 kb positive-sense viral RNA genome that includes a 5' cap into a ribonucleoprotein (RNP) complex known as capsid. Among the 4 major structural proteins of SARS-CoV, the N protein exhibits the highest expression levels in the host cells. We produced a recombinant SARS-CoV N protein (SARSN1) and used it to detect specific antibodies in mice vaccinated with a live probiotic vaccine containing the coronavirus nucleocapsid protein.

查看原文本刊更多论文

重组核衣壳蛋白SARSN1的制备及其在冠状病毒核衣壳蛋白活菌疫苗接种小鼠免疫应答评价中的应用

严重急性呼吸综合征冠状病毒（SARSCoV）的核衣壳(N)蛋白是病毒感染细胞中最丰富的结构蛋白。它的主要功能是将约30 kb的正义病毒RNA基因组（包括一个5'帽）打包到称为衣壳的核糖核蛋白（RNP）复合体中。在SARS-CoV的4种主要结构蛋白中，N蛋白在宿主细胞中的表达量最高。我们制备了一种重组SARS-CoV N蛋白（SARSN1），并用它在接种含有冠状病毒核衣壳蛋白的活益生菌疫苗的小鼠中检测特异性抗体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bulletin of Experimental Biology and Medicine 医学-医学：研究与实验

CiteScore

1.50

自引率

14.30%

发文量

265

审稿时长

2 months

期刊介绍： Bulletin of Experimental Biology and Medicine presents original peer reviewed research papers and brief reports on priority new research results in physiology, biochemistry, biophysics, pharmacology, immunology, microbiology, genetics, oncology, etc. Novel trends in science are covered in new sections of the journal - Biogerontology and Human Ecology - that first appeared in 2005. World scientific interest in stem cells prompted inclusion into Bulletin of Experimental Biology and Medicine a quarterly scientific journal Cell Technologies in Biology and Medicine (a new Russian Academy of Medical Sciences publication since 2005). It publishes only original papers from the leading research institutions on molecular biology of stem and progenitor cells, stem cell as the basis of gene therapy, molecular language of cell-to-cell communication, cytokines, chemokines, growth and other factors, pilot projects on clinical use of stem and progenitor cells. The Russian Volume Year is published in English from April.